$SUPN News

Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript

Supernus Pharmaceuticals, Inc. (SUPN) Indivior Pharmaceuticals, Inc., - M&A Call - Slideshow

SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?

Supernus Pharmaceuticals Inc (SUPN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth ...

Supernus and Indivior merge to create scaled, CNS-focused entity

Supernus Pharmaceuticals Earnings: What To Look For From SUPN

Supernus Pharmaceuticals, Inc. (SUPN) M&A Call Transcript

Supernus Pharmaceuticals Q2 Earnings Call Highlights

Compared to Estimates, Supernus (SUPN) Q2 Earnings: A Look at Key Metrics

Supernus Shares Jump After Revenue Beat, Higher Guidance and Indivior Merger Announcement

Supernus Pharmaceuticals (SUPN) Matches Q2 Earnings Estimates

Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Q2 CY2026 Sales, Stock Jumps 24.9%

Supernus Announces Second Quarter 2026 Financial Results

UPDATE: Supernus Pharmaceuticals Q2 Adj. EPS $0.53 Beats $0.42 Estimate

Supernus Pharmaceuticals (SUPN) Expected to Beat Earnings Estimates: Should You Buy?

Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026

Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD

Strength Seen in Supernus (SUPN): Can Its 5.2% Jump Turn into More Strength?

Cantor Fitzgerald Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $67

Branded Pharmaceuticals Stocks Q1 Teardown: Supernus Pharmaceuticals (NASDAQ:SUPN) Vs The Rest